Tests a new PET scan tracer for CXCR4-expressing blood cancers
Tests a new imaging tracer, 18F-BL40, in people with certain lymphomas or myeloma.
Plain-language title generated from the registry record
Registry title: Preliminary Assessment of [18F]BL40 in PET/CT Scans
Key facts
- Where
- Vancouver, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a newly diagnosed or returned blood cancer such as lymphoma, multiple myeloma or chronic lymphocytic leukemia. Everyone gets two PET/CT scans, one with 18F-BL40 and one with 18F-FDG.
- Age
- 19 years or older (up to 100 years)
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed or recurrent cancer: diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia/small cell lymphoma, or Waldenström Macroglobulinemia
Main reasons for not taking part
- Pregnant or breast-feeding
- Medically unstable, for example acute illness or unstable vital signs
- Unable to lie flat on the back for the whole scan
- Weight above the PET/CT bed limit of 204.5 kg (451 lb), or unable to fit through the scanner opening of 70 cm (28 in)
- History of uncontrolled allergic reactions, or known or expected allergy to [18F]BL40 or its ingredients
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 100 years old?
Source: NCT06224309, who can take part
Where in Canada
- BC CancerVancouver, CanadaContact: Pavithraa RaviTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- British Columbia Cancer Agency
- Trial code
- NCT06224309
- Record updated
- 1 October 2026
- Original description
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease.Read full original descriptionShow less
A Phase 2 Study to Evaluate the in Vivo Biodistribution, Radiation Dosimetry and a Preliminary Assessment of the Diagnostic Performance of [18F]BL40
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease.
This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans:
18F-BL40 and 18F-FDG as part of this study.
Inclusion: Age ≥19 years; Life expectancy ≥3 months; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:; Diffuse large B-Cell lymphoma; Multiple myeloma; Mantle cell lymphoma; Marginal zone lymphoma; Chronic lymphocytic leukemia/small cell lymphoma; Waldenström Macroglobulinemia.
Exclusion: Medically unstable (e.g., acute illness, unstable vital signs); Participants with a history of uncontrolled allergic reactions and/or known or expected hypersensitivity to the peptide diagnostic [18F]BL40 or any of its excipients; Pregnant or breast-feeding; Unable to lie supine for the duration of imaging; Unable to provide written consent; Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm).